In addition, we preliminarily tested the therapeutic potential of a novel anti-oxidant tetra-aza macrocyclic ligand, L2 (3,6,9,15-tetraazabicyclo [9.3.1]penta-deca-1(15),11,13-trien-13-ol) [31], to prevent hypoglycemia-induced Nrf2 down-regulation. Here, NFE2L2 is linked to Hypoglycemia.